Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab monotherapy and combination with zimberelimab in advanced solid tumors
NCT03628677Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Sep 2018
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of domvanalimab in solid tumor (advanced stage) (6 arms), sponsored by Arcus Biosciences. Primary endpoint: Treatment Emergent Adverse Events. Started Sep 2018; status: completed.
02
Drugs
domvanalimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03628677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628677.